胃镜下钛夹标记在不可切局部晚期食管癌患者进行根治性调强放疗时靶区勾画的价值研究

摘要/Abstract

摘要：

目的：探讨胃镜下钛夹标记在不可切局部晚期食管癌患者进行根治性调强放疗时靶区勾画的价值。方法：选取2021年1~12月我院收治行根治性调强放疗的不可切局部晚期食管癌患者150例为研究对象，按随机数字表法分为对照一组、对照二组及观察组，每组各50例，比较3组患者靶区勾画效果，评估放疗6周后近期疗效，统计不良反应，随访至2024年6月，分析远期预后，评定记录无进展生存期（FPS）及总生存期（OS）情况。结果：3组患者病灶长度、GTV、CTV比较，差异有统计学意义（P<0.05），观察组、对照二组患者病灶长度、GTV、CTV均高于对照一组患者（P<0.05），观察组与对照二组患者病灶长度、GTV比较，差异无统计学意义（P>0.05），但观察组患者CTV低于对照二组患者（P<0.05）；3组患者治疗总有效率比较，差异有统计学意义（P<0.05），且观察组患者总有效率为96.00%，高于对照一组患者的84.00%（P<0.05）；3组患者不良反应情况比较，差异无统计学意义（P>0.05）；随访截至2024年6月，对照一组患者PFS 1~17个月（9个月）、OS 2~31个月（15个月）；对照二组患者PFS 1~16个月（10个月）、OS 2~34个月（15个月）；观察组患者PFS 3~20个月（12个月）、OS 3~44个月（22个月），经Kaplan-Meier生存曲线显示，观察组患者PFS、OS长于对照一组和对照二组患者（P<0.05）。结论：胃镜下钛夹标记有助于精准勾画不可切局部晚期食管癌患者靶区，可避免食管钡餐造影定位后放疗剂量不充分以及CT扫描定位后正常器官受照剂量增多的影响，可获可靠近期疗效，且远期预后良好。

关键词: 局部晚期, 食管癌, 胃镜, 钛夹, 调强放疗, 靶区勾画

Abstract:

Objective： To evaluate the value of titanium clamp labeling under gastroscopy in target delineation of radical intensity modulated radiotherapy （IMRT） in patients with inoperable locally advanced esophageal cancer.Methods： A total of 150 patients with inoperable locally advanced esophageal cancer who received radical intensity modulated radiotherapy in our hospital from January 2021 to December 2021 were selected as the research objects. They were divided into the control group 1， control group 2 and observation group according to random number table method. Esophageal barium meal imaging was performed before radiotherapy in control group 1， and CT scanning was performed in control group 2 before radiotherapy. The observation group was labeled with titanium clamp under gastroscope before radiotherapy， and the delineation effect of target areas was compared among the three groups. The short-term efficacy after 6 weeks of radiotherapy was evaluated， adverse reactions were observed， and the long-term prognosis was analyzed by recording progression-free survival （PFS） and overall survival （OS） for evaluation.Results： There were statistically significant differences in lesion length， GTV， and CTV among the three groups of patients （P<0.05）. The lesion length， GTV， and CTV of the observation group and the control group 2 were higher than those of the control group 1 （P<0.05）. There was no statistically significant difference in lesion length and GTV between the observation group and the control group 2 （P>0.05）， but the CTV of the observation group was lower than that of the control group 2 （P<0.05）. The total effective rate of the three groups of patients was compared， and the difference was statistically significant （P<0.05）. The total effective rate of the observation group was 96.00%， which was higher than that of the control group 1 （84.00%）（P<0.05）. There was no statistically significant difference in adverse reactions among the three groups of patients （P>0.05）. Follow up until June 2024， the control group 1 patients had PFS of 1-17 months （9 months） and OS of 2-31 months （15 months）， the PFS of the control group 2 patients was 1-16 months （10 months） and OS was 2-34 months （15 months）， and the PFS and OS of the observation group patients were 3-20 months （12 months） and 3-44 months （22 months）， respectively. Kaplan-Meier survival curves showed that the PFS and OS of the observation group patients were longer than those of the control group 1 and control group 2 patients （P<0.05）.Conclusion： Titanium clamp labeling under gastroscope is helpful to accurately delineate the target area of patients with unresectable locally advanced esophageal cancer， which can avoid the influence of inadequate radiotherapy dose after esophageal barium meal imaging and increased radiation dose of normal organs after CT scan localization， and can obtain reliable short-term efficacy and good long-term prognosis.

Key words: Local late stage； , Esophageal cancer； , Gastroscope； , Titanium clamp； , Intensity modulated radiotherapy； , Target delineation

中图分类号:

R735

兰堃田, 郭芮菲, 陈姣红, 员建中.

胃镜下钛夹标记在不可切局部晚期食管癌患者进行根治性调强放疗时靶区勾画的价值研究 [J]. 中国医药导刊, 2024, 26(8): 808-813.

LAN Kuntian, GUO Ruifei, CHEN Jiaohong, YUAN Jianzhong.

The Value of Titanium Clamp Labeling Under Gastroscope in Target Delineation of Radical Intensity Modulated Radiotherapy for Patients with Inoperable Locally Advanced Esophageal Cancer [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2024, 26(8): 808-813.

参考文献

［1］ Ajani JA， D'Amico TA， Bentrem DJ， et al. Esophageal and esophagogastric junction cancers， version 2.2023， NCCN clinical practice guidelines in oncology［J］. J Natl Compr Canc Netw，2023， 21（4）：393-422.

［2］ Uhlenhopp DJ， Then EO， Sunkara T， et al. Epidemiology of esophageal cancer： update in global trends， etiology and risk factors［J］. Clin J Gastroenterol，2020，13（6）：1010-1021.

［3］ Morgan E， Soerjomataram I， Rumgay H， et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040： new estimates from GLOBOCAN 2020［J］. Gastroenterology，2022，163（3）：649-658.

［4］ Niu C， Liu Y， Wang J， et al. Risk factors for esophageal squamous cell carcinoma and its histological precursor lesions in China：a multicenter cross-sectional study［J］.BMC Cancer，2021，21（1）：1034.

［5］ Zang Z，Liu Y，Wang J，et al.Dietary patterns and severity of symptom with the risk of esophageal squamous cell carcinoma and its histological precursor lesions in China： a multicenter cross-sectional latent class analysis［J］. BMC Cancer，2022，22（1）：95.

［6］ Obermannová R，Alsina M，Cervantes A，et al.Oesophageal cancer：ESMO clinical practice guideline for diagnosis， treatment and follow-up［J］.Ann Oncol，2022，33（10）：992-1004.

［7］ Chang CL，Lin KC，Chen WM，et al.Correspondence：intensity-modulated rroton therapy versus Intensity-Modulated radiotherapy for inoperable esophageal squamous cell carcinoma： methodologic issues［J］.J Thorac Oncol，2024，19（4）：e2-e4.

［8］ Li H，Gu D，Du M，et al.Postoperative concurrent chemoradiotherapy for locally advanced thoracic esophageal squamous cell carcinoma：a phase II clinical trial［J］. Front Oncol，2022， 12：900443.

［9］屈超. 内镜下钛夹标记在早期食管癌放疗中的应用［J］. 国际医学放射学杂志，2020，43（3）：331-334.

［10］ Rochigneux P， Tyran M， Autret A， et al. Impact of fiducial markers placement on the delineation of target volumes in radiation therapy for oesophageal cancer： FIDUCOR study［J］. Front Oncol，2022，12：1012712.

［11］ Tan L， Feng J， Zhao Q， et al. Preoperative endoscopic titanium clip placement facilitates intraoperative localization of early-stage esophageal cancer or severe dysplasia［J］. World J Surg Oncol， 2017， 15（1）：145.

［12］中华人民共和国国家卫生健康委员会. 食管癌诊疗规范（2018年版）［J］. 肿瘤综合治疗电子杂志，2019，5（2）：50-86.

［13］ Rice TW， Ishwaran H， Ferguson MK，et al.Cancer of the esophagus and esophagogastric junction： an eighth edition staging primer［J］. J Thorac Oncol， 2017，12（1）：36-42.

［14］ Villa A， Vollemans M， De Moraes A， et al. Concordance of the WHO， RTOG， and CTCAE v4.0 grading scales for the evaluation of oral mucositis associated with chemoradiation therapy for the treatment of oral and oropharyngeal cancers［J］. Support Care Cancer，2021，29（10）：6061-6068.

［15］ Hou Z， Gao S， Liu J， et al. Clinical evaluation of deep learning-based automatic clinical target volume segmentation：a single-institution multi-site tumor experience［J］.Radiol Med，2023，128（10）：1250-1261.

［16］ Jin D， Guo D， Ge J， et al. Towards automated organs at risk and target volumes contouring： defining precision radiation therapy in the modern era［J］. J Natl Cancer Cent，2022，2（4）：306-313.

［17］海平，赵仁，杨小荣，等. 三种方法确定食管癌GTV长度的比较研究［J］. 中华放射肿瘤学杂志，2018，27（4）：370-373.

［18］李晓宁，王澜，韩春，等. 食管癌CT图像GTV与三维放疗预后关系分析［J］. 中华放射肿瘤学杂志，2014，23（1）：23-26.

［19］杜文静，李杰，武学勤，等. 内窥镜下钛夹标记定位在早期食管癌放疗中的应用［J］. 肿瘤研究与临床，2014，26（7）：485-487.

［20］ Wang J， Tang L， Lin L， et al. Imaging characteristics of esophageal cancer in multi-slice spiral CT and barium meal radiography and their early diagnostic value［J］. J Gastrointest Oncol， 2022，13（1）：49-55.

［21］ Tan L， Feng J， Zhao Q， et al. Preoperative endoscopic titanium clip placement facilitates intraoperative localization of early-stage esophageal cancer or severe dysplasia［J］. World J Surg Oncol，2017，15（1）：145.

［22］蔡履娟，骆华春，傅志超，等. 内镜下钛夹植入对局部晚期食管癌术前放疗患者靶区勾画和剂量学参数的影响［J］. 国际放射医学核医学杂志，2021，45（11）：682-688.

［23］ Li F，Li Y，Wang X， et al.Inter-observer and intra-observer variability in gross tumor volume delineation of primary esophageal carcinomas based on different combinations of diagnostic multimodal images［J］. Front Oncol，2022，12：817413.

［24］ Dhadham GC， Hoffe S， Harris CL， et al. Endoscopic ultrasound-guided fiducial marker placement for image-guided radiation therapy without fluoroscopy： safety and technical feasibility［J］. Endosc Int Open，2016，4（3）：378-382.

［25］ Fernandez DC， Hoffe SE， Barthel JS， et al. Stability of endoscopic ultrasound-guided fiducial marker placement for esophageal cancer target delineation and image-guided radiation therapy［J］. Pract Radiat Oncol， 2013， 3（1）：32-39.

[1]	张厚莉, 孟伟, 王启飞, 陈文文, 耿涛, 党和勤, 刘宝军. 基于处方模板的食管癌围手术期动态营养支持的建立及应用评价[J]. 中国医药导刊, 2022, 24(6): 593-597.
[2]	鲁燕, 张华, 董霞, 刘晓辉. 中药穴位贴敷联合化疗治疗中晚期食管癌的疗效观察[J]. 中国医药导刊, 2021, 23(2): 91-95.
[3]	代文婷,刘建军,黄勇. 胃和食管双原发癌患者化疗方案的个例分析[J]. , 2019, 21(4): 243-245.
[4]	黄嘉宁,沈洁,黄璐,胡宝英. 虚拟现实技术在常规胃镜检查中的应用价值研究[J]. , 2018, 20(5): 293-295.
[5]	周虹,陈丽. 术后调强放疗对早中期宫颈癌有效性与安全性分析[J]. , 2018, 20(10): 593-597.
[6]	刘孟奇,赵庆书. 两次放疗计划融合在降低食管癌放疗患者肺脏损伤中的作用[J]. , 2016, 18(6): 553-555.
[7]	刘超，吕俊杰，尤振兵，徐达夫，嵇建，胡忠吾. 胸腔镜下食管癌切除术的临床疗效分析[J]. , 2016, 18(4): 339-340.
[8]	周琳,谯波,侯敏,陈波. 晚期食管癌放化治疗联合深部热疗的近期疗效观察[J]. , 2016, 18(1): 1-2.
[9]	张秋生,付景伟. 胸腹腔镜联合手术治疗食管癌患者的临床疗效观察[J]. , 2015, 17(9): 0-0.
[10]	. PET/CT对于食管癌放射治疗的研究进展[J]. , 2012, 14(8): 1311-1313.
[11]	. 早期乳腺癌不同调强适形放疗技术观察[J]. , 2012, 14(8): 1459-1460.
[12]	. 中晚期食管癌同期放化疗36例临床观察[J]. , 2012, 14(7): 0-0.
[13]	. 食管支架选择应用的临床探讨[J]. , 2012, 14(7): 1274-1275.

快速检索引用检索图表检索高级检索